Stryker (SYK) official guidance
Stryker (SYK) official earnings guidance and management outlook. Each figure management stated is shown with its revisions and the source quote.
See the full Filings Intelligence suiteSYKSTRYKER CORPFY2026 · ends 2026-12-31
3 metrics1 raised2 maintainedearnings call · 17h
2026-10-29 21:51:46 UTC15.5% – 16%raised +1.6%-1259 bps – -1209 bps vs FY2025
The third quarter had an adjusted effective tax rate of 16%, and we now expect our full-year effective tax rate to be in the range of 15.5%-16%.
SYK · transcript · Q3 FY2026
2026-10-29 21:51:00 UTCOpen source
2026-07-31 04:00:48 UTC15% – 16%maintained-1309 bps – -1209 bps vs FY2025
For 2026, we continue to expect our full-year effective tax rate to be in the range of 15%-16%.
SYK · transcript · Q2 FY2026
2026-07-31 04:00:00 UTCOpen source
2026-05-01 04:01:09 UTC15% – 16%maintained-1309 bps – -1209 bps vs FY2025
For 2026, we continue to expect our full year effective tax rate to be in the range of 15%-16%.
SYK · transcript · Q1 FY2026
2026-05-01 04:00:00 UTCOpen source
2026-01-30 05:01:13 UTC15% – 16%new
For 2026, we expect our full-year effective tax rate to be in the range of 15%-16%.
SYK · transcript · Q4 FY2025
2026-01-30 05:00:00 UTCOpen source
2026-10-29 21:51:46 UTC$14.8 – $14.9maintained
We now expect full-year organic net sales growth of 6.5%-7%, and adjusted net earnings per share of $14.80-$14.90.
SYK · transcript · Q3 FY2026
2026-10-29 21:51:00 UTCOpen source
2026-10-29 20:12:10 UTC$14.8 – $14.9lowered -1.2%
We are updating our full year 2026 guidance and now expect organic net sales growth(2) in the range of 6.5% to 7.0% and adjusted net earnings per diluted share(2) to be in the range of $14.80 to $14.90.
SYK · EX-99.1 · Q3 FY2026
2026-10-29 20:11:16 UTCOpen source
2026-07-31 04:00:48 UTC$14.95 – $15.1maintained
Considering our year-to-date results, our presence in attractive end markets, largely supporting acute and emergent procedures, and durable demand for our capital products, we are narrowing our full-year guidance and now expect organic net sales growth to be in the range of 8.3%-9.3%, and adjusted net earnings per share to be in the range of $14.95-$15.10.
SYK · transcript · Q2 FY2026
2026-07-31 04:00:00 UTCOpen source
2026-07-30 20:10:21 UTC$14.95 – $15.1raised +0.2%
We are narrowing our full year 2026 guidance and now expect organic net sales growth(2) in the range of 8.3% to 9.3% and adjusted net earnings per diluted share(2) in the range of $14.95 to $15.10.
SYK · EX-99.1 · Q2 FY2026
2026-07-30 20:09:48 UTCOpen source
2026-05-01 04:01:09 UTC$14.9 – $15.1maintained
We continue to expect organic net sales growth to be in the range of 8%-9.5%, and adjusted net earnings per share to be in the range of $14.90-$15.10.
SYK · transcript · Q1 FY2026
2026-05-01 04:00:00 UTCOpen source
2026-04-30 20:08:09 UTC$14.9 – $15.1maintained
We are maintaining our full year 2026 guidance of organic net sales growth(2) in the range of 8.0% to 9.5% and adjusted net earnings per diluted share(2) in the range of $14.90 to $15.10.
SYK · EX-99.1 · Q1 FY2026
2026-04-30 20:07:43 UTCOpen source
2026-01-30 05:01:13 UTC$14.9 – $15.1maintained
Given our strong exit from 2025, our presence in healthy end markets, sustained procedural volumes, and strong demand for our capital products, we expect 2026 organic net sales growth to be in the range of 8%-9.5% and adjusted net earnings per share to be in the range of $14.90-$15.10.
SYK · transcript · Q4 FY2025
2026-01-30 05:00:00 UTCOpen source
2026-01-29 21:11:36 UTC$14.9 – $15.1new
Based on our momentum exiting 2025, healthy procedural volumes and strong demand for our capital products, we expect 2026 organic net sales growth(2) to be in the range of 8.0% to 9.5% and adjusted net earnings per diluted share(2) to be in the range of $14.90 to $15.10.
SYK · EX-99.1 · Q4 FY2025
2026-01-29 21:11:00 UTCOpen source
2026-10-29 21:51:46 UTC6.5% – 7%maintained6.5% – 7% vs FY2025
We now expect full-year organic net sales growth of 6.5%-7%, and adjusted net earnings per share of $14.80-$14.90.
SYK · transcript · Q3 FY2026
2026-10-29 21:51:00 UTCOpen source
2026-10-29 20:12:10 UTC6.5% – 7%lowered -23.3%6.5% – 7% vs FY2025
We are updating our full year 2026 guidance and now expect organic net sales growth(2) in the range of 6.5% to 7.0% and adjusted net earnings per diluted share(2) to be in the range of $14.80 to $14.90.
SYK · EX-99.1 · Q3 FY2026
2026-10-29 20:11:16 UTCOpen source
2026-07-31 04:00:48 UTC8.3% – 9.3%maintained8.3% – 9.3% vs FY2025
Considering our year-to-date results, our presence in attractive end markets, largely supporting acute and emergent procedures, and durable demand for our capital products, we are narrowing our full-year guidance and now expect organic net sales growth to be in the range of 8.3%-9.3%, and adjusted net earnings per share to be in the range of $14.95-$15.10.
SYK · transcript · Q2 FY2026
2026-07-31 04:00:00 UTCOpen source
2026-07-30 20:10:21 UTC8.3% – 9.3%raised +0.6%8.3% – 9.3% vs FY2025
We are narrowing our full year 2026 guidance and now expect organic net sales growth(2) in the range of 8.3% to 9.3% and adjusted net earnings per diluted share(2) in the range of $14.95 to $15.10.
SYK · EX-99.1 · Q2 FY2026
2026-07-30 20:09:48 UTCOpen source
2026-05-01 04:01:09 UTC8% – 9.5%maintained8% – 9.5% vs FY2025
We continue to expect organic net sales growth to be in the range of 8%-9.5%, and adjusted net earnings per share to be in the range of $14.90-$15.10.
SYK · transcript · Q1 FY2026
2026-05-01 04:00:00 UTCOpen source
2026-04-30 20:08:09 UTC8% – 9.5%maintained8% – 9.5% vs FY2025
We are maintaining our full year 2026 guidance of organic net sales growth(2) in the range of 8.0% to 9.5% and adjusted net earnings per diluted share(2) in the range of $14.90 to $15.10.
SYK · EX-99.1 · Q1 FY2026
2026-04-30 20:07:43 UTCOpen source
2026-01-30 05:01:13 UTC8% – 9.5%maintained8% – 9.5% vs FY2025
Given our strong exit from 2025, our presence in healthy end markets, sustained procedural volumes, and strong demand for our capital products, we expect 2026 organic net sales growth to be in the range of 8%-9.5% and adjusted net earnings per share to be in the range of $14.90-$15.10.
SYK · transcript · Q4 FY2025
2026-01-30 05:00:00 UTCOpen source
2026-01-29 21:11:36 UTC8% – 9.5%new8% – 9.5% vs FY2025
Based on our momentum exiting 2025, healthy procedural volumes and strong demand for our capital products, we expect 2026 organic net sales growth(2) to be in the range of 8.0% to 9.5% and adjusted net earnings per diluted share(2) to be in the range of $14.90 to $15.10.
SYK · EX-99.1 · Q4 FY2025
2026-01-29 21:11:00 UTCOpen source
SYKSTRYKER CORPQ4 FY2026 · ends 2026-12-31
1 metric1 newearnings call · 17h
2026-10-29 21:51:46 UTCa similar overall organic growth rate for the company in Q4 as we achieved in Q3new
Our updated organic sales guidance anticipates a similar overall organic growth rate for the company in Q4 as we achieved in Q3.
SYK · transcript · Q3 FY2026
2026-10-29 21:51:00 UTCOpen source
SYKSTRYKER CORPFY2026 · ends 2026-12-31
1 metric1 loweredearnings call · 17h
2026-10-29 21:51:46 UTC$400Mlowered -4.8%
We now expect adjusted other income and expense to be approximately $400 million for the full year.
SYK · transcript · Q3 FY2026
2026-10-29 21:51:00 UTCOpen source
2026-07-31 04:00:48 UTC$420Mmaintained
We continue to expect our full year 2026 adjusted other income and expense to be approximately $420 million.
SYK · transcript · Q2 FY2026
2026-07-31 04:00:00 UTCOpen source
2026-05-01 04:01:09 UTC$420Mnew
We continue to expect our full year 2026 adjusted other income and expense to be approximately $420 million.
SYK · transcript · Q1 FY2026
2026-05-01 04:00:00 UTCOpen source
SYKSTRYKER CORPQ4 FY2026 · ends 2026-12-31
1 metric1 newearnings call · 17h
2026-10-29 21:51:46 UTCstrong growthnew
We are expecting strong growth for Trauma and Extremities in the fourth quarter.
SYK · transcript · Q3 FY2026
2026-10-29 21:51:00 UTCOpen source
SYKSTRYKER CORPFY2027 · ends 2027-12-31
1 metric1 newearnings call · 17h
2026-10-29 21:51:46 UTCgrowth at the high end of our marketsnew
While we will not provide formal guidance until early next year, we do expect to deliver growth at the high end of our markets.
SYK · transcript · Q3 FY2026
2026-10-29 21:51:00 UTCOpen source
SYKSTRYKER CORPFY2026 · ends 2026-12-31
3 metrics3 newearnings call · 2026-05-01 04:01:09 UTC
2026-05-01 04:01:09 UTC70% – 80%new
Yeah. We're still thinking about it in that 70%-80% range.
SYK · transcript · Q1 FY2026
2026-05-01 04:00:00 UTCOpen source
2026-01-30 05:01:13 UTC$420Mnew
For 2026, we expect our full-year other income and expense to be approximately $420 million.
SYK · transcript · Q4 FY2025
2026-01-30 05:00:00 UTCOpen source
2026-01-30 05:01:13 UTC$400Mnew
In addition, we expect full-year tariff impacts to be approximately $400 million, which includes an incremental $200 million compared to 2025 that will be realized in the first half of the year.
SYK · transcript · Q4 FY2025
2026-01-30 05:00:00 UTCOpen source
SYKSTRYKER CORPH2 FY2026 · ends 2026-06-30
1 metric1 newearnings call · 2026-01-30 05:01:13 UTC
2026-01-30 05:01:13 UTC$200Mnew
In addition, we expect full-year tariff impacts to be approximately $400 million, which includes an incremental $200 million compared to 2025 that will be realized in the first half of the year.
SYK · transcript · Q4 FY2025
2026-01-30 05:00:00 UTCOpen source
SYKSTRYKER CORPFY2025 · ends 2025-12-31
5 metrics4 new1 maintainedearnings call · 2025-10-31 04:01:23 UTC
2025-10-31 04:01:23 UTC15%new71 bps vs FY2024
For 2025, we now expect our full year effective tax rate to be at the lower end of our previously guided range of 15%-16%.
SYK · transcript · Q3 FY2025
2025-10-31 04:00:00 UTCOpen source
2025-10-31 04:01:23 UTC$13.5 – $13.6maintained
Considering our year-to-date results, continued strong demand for our products, and our operational momentum, we are raising our full year guidance and now expect organic net sales growth of 9.8% to 10.2% and adjusted earnings per share to be in the range of $13.50-$13.60.
SYK · transcript · Q3 FY2025
2025-10-31 04:00:00 UTCOpen source
2025-10-30 20:16:16 UTC$13.5 – $13.6new
Based on our sales momentum, sustained demand for our products and commitment to margin expansion, we are raising our full year 2025 guidance and now expect organic net sales growth(2) of 9.8% to 10.2% and adjusted net earnings per diluted share(2) to be in the range of $13.50 to $13.60.
SYK · EX-99.1 · Q3 FY2025
2025-10-30 20:15:42 UTCOpen source
2025-10-31 04:01:23 UTC100 bpsnew100 bps vs FY2024
We are firmly on track to deliver a second consecutive year of 100 basis points of adjusted operating margin expansion, backed by strong execution and conviction in the sustained growth and earnings power of our businesses.
SYK · transcript · Q3 FY2025
2025-10-31 04:00:00 UTCOpen source
2025-10-31 04:01:23 UTC10%new10% vs FY2024
We continue to expect Medical to achieve 10% organic sales growth this year while we manage the previously discussed supply chain disruptions affecting our Emergency Care business.
SYK · transcript · Q3 FY2025
2025-10-31 04:00:00 UTCOpen source
2025-10-31 04:01:23 UTC$415Mnew
We now expect our full year 2025 adjusted other income and expense to be approximately $415 million.
SYK · transcript · Q3 FY2025
2025-10-31 04:00:00 UTCOpen source
SYKSTRYKER CORPFY2025
1 metric1 newearnings call · 2025-10-31 04:01:23 UTC
2025-10-31 04:01:23 UTC$590Mnew
Inari remains on track to deliver double-digit pro forma sales growth in 2025 and approximately $590 million in sales for the 10 months this year as a part of Stryker.
SYK · transcript · Q3 FY2025
2025-10-31 04:00:00 UTCOpen source
SYKSTRYKER CORPFY2025 · ends 2025-12-31
1 metric1 newearnings call · 2025-10-31 04:01:23 UTC
2025-10-31 04:01:23 UTCdouble-digit pro forma sales growthnew10% – 19% vs FY2024
Inari remains on track to deliver double-digit pro forma sales growth in 2025 and approximately $590 million in sales for the 10 months this year as a part of Stryker.
SYK · transcript · Q3 FY2025
2025-10-31 04:00:00 UTCOpen source
SYKSTRYKER CORPQ4 FY2025 · ends 2025-12-31
1 metric1 newearnings call · 2025-10-31 04:01:23 UTC
2025-10-31 04:01:23 UTCdouble-digit growthnew
We do expect double-digit growth in Q4 and then again in Q1.
SYK · transcript · Q3 FY2025
2025-10-31 04:00:00 UTCOpen source
SYKSTRYKER CORPQ1 FY2026 · ends 2026-03-31
1 metric1 newearnings call · 2025-10-31 04:01:23 UTC
2025-10-31 04:01:23 UTCdouble-digit growthnew
We do expect double-digit growth in Q4 and then again in Q1.
SYK · transcript · Q3 FY2025
2025-10-31 04:00:00 UTCOpen source